Suppr超能文献

DICER1 突变在中、低分化 Sertoli-Leydig 细胞瘤中普遍存在。

DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors.

机构信息

*Department of Human Genetics, McGill University †Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital ¶Research Institute of the McGill University Health Centre, Montréal, QC, Canada ‡Department of Laboratory Medicine and Pathobiology, University Health Network, University of Toronto, Toronto, ON, Canada §Department of Pathology, Belfast Health and Social Care Trust, Royal Group of Hospitals Trust, Belfast, United Kingdom ∥School for Women's and Infants' Health, University of Western Australia, Perth, WA, Australia.

出版信息

Am J Surg Pathol. 2017 Sep;41(9):1178-1187. doi: 10.1097/PAS.0000000000000895.

Abstract

Ovarian Sertoli-Leydig cell tumors (SLCTs) are uncommon sex cord-stromal tumors associated with both germ-line and somatic DICER1 mutations, the frequency of which has varied widely in different studies (0% to 62.5%). The current World Health Organization Classification includes 3 histologic types of SLCTs (well-differentiated, moderately differentiated, and poorly differentiated); heterologous elements and/or retiform patterns may be present in moderately and poorly differentiated neoplasms. We investigated the frequency of DICER1 mutations in a series of 38 ovarian tumors initially diagnosed as SLCTs, and explored whether identified mutations were associated with specific morphologic features. Specialist pathology review performed blinded to molecular results confirmed 34 tumors to be SLCTs (22 moderately differentiated, 8 poorly differentiated; 4 well-differentiated), while the remaining 4 neoplasms were considered not to represent SLCTs. Of the 34 cases diagnosed as SLCTs, 30 (88%) harbored ≥1 DICER1 mutation. All 30 moderately differentiated/poorly differentiated SLCTs contained mutations, but we did not find deleterious DICER1 mutations in the 4 well-differentiated SLCTs. Our study reports the highest DICER1 mutation frequency to date in SLCTs, with 100% of moderately differentiated and poorly differentiated tumors being DICER1-mutated. This suggests that DICER1 mutation may be a defining feature of these neoplasms. Although the number of cases is limited, well-differentiated SLCTs appear to be DICER1-independent. Moderately differentiated and poorly differentiated SLCT components often coexist with each other and form part of a spectrum, while well-differentiated SLCTs usually occur in pure form, suggesting that fundamentally, these represent 2 separate and independent tumor types with a different pathogenesis. We suggest that all patients with ovarian SLCTs undergo germ-line DICER1 mutation testing.

摘要

卵巢 Sertoli-Leydig 细胞瘤 (SLCT) 是一种罕见的性索-间质肿瘤,与种系和体细胞 DICER1 突变有关,不同研究中的频率差异很大 (0% 至 62.5%)。目前的世界卫生组织分类包括 3 种 SLCT 组织学类型 (分化良好型、中度分化型和低度分化型);中、低度分化型肿瘤可能存在异源成分和/或网状模式。我们研究了一系列最初诊断为 SLCT 的 38 例卵巢肿瘤中 DICER1 突变的频率,并探讨了鉴定出的突变是否与特定的形态特征相关。在不了解分子结果的情况下进行的专科病理学复查证实,34 例肿瘤为 SLCT (22 例为中度分化,8 例为低度分化;4 例为分化良好型),而其余 4 例肿瘤被认为不代表 SLCT。在诊断为 SLCT 的 34 例病例中,有 30 例 (88%)存在 ≥1 个 DICER1 突变。所有 30 例中、低度分化 SLCT 均存在突变,但我们未在 4 例分化良好型 SLCT 中发现有害的 DICER1 突变。我们的研究报告了迄今为止 SLCT 中最高的 DICER1 突变频率,100%的中、低度分化肿瘤均存在 DICER1 突变。这表明 DICER1 突变可能是这些肿瘤的一个特征。尽管病例数有限,但分化良好的 SLCT 似乎与 DICER1 无关。中、低度分化 SLCT 成分通常相互共存并形成一个谱,而分化良好的 SLCT 通常以纯形式出现,这表明从根本上讲,这些代表 2 种不同的、独立的肿瘤类型,具有不同的发病机制。我们建议所有卵巢 SLCT 患者均进行种系 DICER1 突变检测。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验